×
Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    Asia Pacific Contraceptives Market Forecast 2028 By Product (Drugs {Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives}, Devices {Condoms [Male, Female], Diaphragms, Contraceptive Sponges, Vaginal Rings, Subdermal Implants, Intra-uterine Devices [Copper IUD, Hormonal IUD]}), Research Report, Country Outlook (China, Japan, India, Australia), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
    Published Date: June 2022   |   Report ID: GR2140   |   Delivery: PDF  Request Free Sample

    Asia Pacific Contraceptives Market size crossed USD 6.6 billion in 2021 and is projected to exhibit a CAGR of 10.2% between 2022 and 2028. The increasing prevalence of STDs and STIs in Asia Pacific region is projected to fuel the market demand.

    Asia Pacific Contraceptives Market

    Get more details on this report - Request Free Sample PDF

    Adoption of supportive initiatives by government authorities along with public organizations is expected to drive the adoption of contraceptives. These initiatives aid in prevention of STDs and STIs, targeting those at greatest risk and are crucial to curb the spread of HIV. For instance, the Challenge Initiative (TCI) is a demand-based, family planning tool that is used for sustainable scale and impact that enables governments to lead family planning implementation. This tool is currently active in several developing countries, including certain countries in Asia.

    Asia Pacific Contraceptives Market, By Product

    The devices segment revenue will cross USD 11,401 million by 2028, due to the rise in the reproductive population and surging prevalence of STIs in the region. Owing to high reproductive population, certain countries in the region are amongst the highest users of contraceptives.

    According to the United Nations’ 2019 report, in countries such as India, Japan, South Korea, Indonesia, and other, more than 50% of the females of reproductive age (aged 15-49 years) use contraceptives. China and Japan are amongst the highest users of contraceptive devices including male condoms accounting for more than 20% of the overall use of contraceptives. In addition to this, the increasing prevalence of STDs in the region is further set to promote the demand for contraceptives.

    Asia Pacific Market, By Country

    China contraceptives market accounted for 29.6% revenue share in 2021 and will exceed USD 4,310 million revenue by 2028, attributed to the increasing prevalence of STDs and surged use of contraceptives in the country. Acquired immunodeficiency syndrome (AIDS) pertaining to HIV infection, gonorrhoea, and syphilis are the three commonly prevalent STDs in the country.

    As per the Law of the Peoples’ Republic of China on Prevention and Control of Infectious Diseases, diagnosed STDs are required to be reported to national surveillance systems. The surveillance systems reported that in 2019, there were 50,874 new cases of genital chlamydial infection, corresponding to 55.32, every 100,000 individuals. This estimate further highlights a 9.98% increase as compared to 2018. Moreover, the highest incidence rate of this infection ranges from 137.49–233.37 cases, every 100,000 individuals.

    Competitive Industry Landscape

    Major players involved in the Asia Pacific contraceptives market are Allergan Plc, Bayer Corporation, Cooper Surgical, Inc., Church & Dwight Co., Inc., Mayer Laboratories, Inc., Merck & Co. Inc., Pfizer, Reckitt Benckiser Group Plc, and Teva Pharmaceuticals Industries Ltd.

    These companies are implementing several organic and inorganic strategies such as product launches and partnerships for garnering maximum market share and strengthening their industrial presence.
     


    Frequently Asked Question(FAQ) :

    What is the contraceptives market worth in Asia Pacific?
    The industry size for contraceptives in Asia Pacific had crossed USD 6.6 billion in 2021 and will record a CAGR of more than 10.2% between 2022-2028 with rising burden of STDs and STIs in the region.
    Why is the contraceptive devices industry growing?
    The industry share for contraceptives in Asia Pacific from the devices product segment is expected to exceed USD 11.4 billion by 2028 driven by the expanding reproductive population and increasing prevalence of STIs in the region.
    What is the size of China contraceptives sector?
    China accounted for over 29.6% of APAC industry revenue share in 2021 and will surpass USD 4,310 million in annual revenue by 2028, impelled by the rising cases of HIV infection, gonorrhoea, and syphilis in the country.
    Who manufactures contraceptives in Asia Pacific?
    Allergan Plc, Bayer Corporation, Cooper Surgical, Inc., Church & Dwight Co., Inc., Inc., Merck & Co. Inc., Pfizer, Reckitt Benckiser Group Plc, and Teva Pharmaceuticals Industries Ltd. are some of the well-known the industry players in APAC.

    Get this research report on Asia Pacific Contraceptives Market customized according to your business requirements.

    report-purchase - logo Buy Now

    Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

      (+1)-208-273-9852

     [email protected]